We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Under the terms of the settlement, the companies will pay their own respective legal fees and Bayer will not make any claims for the $173 million payment. Read More
Vaccine supplies to poorer countries have been significantly impacted by the worsening COVID-19 crisis in India, a major supplier to those countries. Read More
Takeda Pharmaceutical subsidiary Baxalta and Bayer have hashed out a settlement that will dismiss a 2019 jury verdict that ordered Baxalta to pay $173 million for infringing on Bayer’s patents for the hemophilia A drug Adynovate, with Bayer agreeing not to pursue the money it is owed. Read More
Continuing investment and efforts to discover and develop novel drugs by small and large pharmaceutical companies drove a record launch of 66 new drugs globally in 2020, with particular success in oncology and rare diseases, according to a new IQVIA analysis. Read More
Almost half of all pharmaceutical companies had more than 1,000 leaked employee credentials exposed on the deep web in the past three months, and nearly 10 percent of pharma manufacturers are now considered highly susceptible to a ransomware attack. Read More
Agenus expects to file an Investigational New Drug application with the FDA during this quarter, with BMS prepping AGEN1777 as a possible nonsmall-cell lung cancer treatment. Read More
Novartis subsidiary Sandoz failed to persuade the U.S. Supreme Court to review a federal circuit ruling that blocked the drugmaker from launching a copycat drug of Amgen’s autoimmune blockbuster Enbrel (etanercept). Read More
Although prominent COVID-19 vaccine makers have argued for ramping up production to help meet global vaccine needs as an alternative to waiving intellectual property (IP) rights, several pharma companies, including the world’s biggest generics maker, have been unable to secure such manufacturing arrangements. Read More
The pharmaceutical industry has engaged in record-breaking spending on lobbying efforts in the first quarter of 2021, according to a nonpartisan lobbying research group, as Democrats continue their push for passage of drug pricing measures. Read More